In the largest single enforcement action in the agency's history targeting weight-loss medications, the FDA issued 30 warning letters to telehealth companies and compounding pharmacies in March 2026 for illegally marketing compounded semaglutide and tirzepatide.

The action came days after the FDA officially declared the semaglutide shortage resolved—eliminating the legal basis under which 503A compounding pharmacies had been permitted to produce copies of the branded drugs.

30
Warning letters issued in a single week—more GLP-1 enforcement activity than the prior decade combined. Companies named include Beluga Health, OpenLoop, Ivim Health, and 27 others.
Source: FDA.gov, March 2026

The Compounding Loophole, Explained

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can produce copies of branded drugs during a declared shortage. The semaglutide shortage, which began in 2022, created a multi-billion-dollar compounding market virtually overnight. Prices ranged from $150–$400/month versus Wegovy's then-$1,350 list price.

With shortages resolved, that legal basis evaporated. Companies continuing to market compounded semaglutide are now operating outside FDA guidance.

Sponsored · Teleios Health

Your GLP-1 Should Come With a Protocol

Labs, protein targets, resistance training, and physician oversight. The complete system starting at $99/mo.

Start Your Program →

What This Means for Patients

An estimated 2–3 million Americans are currently on compounded GLP-1 medications. They face several immediate concerns:

  • Supply disruption: Compounding pharmacies are required to wind down production. Patients may lose access within 60–90 days.
  • Safety uncertainty: Compounded medications were never FDA-approved. Potency, sterility, and consistency varied by facility.
  • Transition planning: Patients should work with their physician to transition to branded medications or comprehensive programs that include FDA-approved therapies.
Patient Advisory

If your provider is still offering "custom compounded" GLP-1 medications, ask to see their 503B outsourcing facility registration. 503B facilities (not 503A) may continue compounding under stricter FDA oversight. If they cannot produce documentation, consider transitioning to a physician-led program using FDA-approved medications.

Industry Reaction

Compounding pharmacy stocks dropped 40–60% following the announcement. Several companies, including Hims & Hers Health, announced plans to pivot to branded medication partnerships. The telehealth sector faces a fundamental reckoning: the business model built on cheap compounded medications has lost its regulatory foundation.